世界の止血剤市場は、売上ベースで2023 年に 27 億ドル相当と推定され、2028 年までに 37 億ドルに達する見込みで、2023 年から 2028 年までのCAGRは6.7% と予想されます。このレポートは、業界動向分析で構成され、業界の動向、価格分析、特許分析、カンファレンスとウェビナーの資料、主要な利害関係者、市場の購買行動が含まれています。
								
						目次
						
	TABLE OF CONTENTS
	1 INTRODUCTION (Page No. - 21)
	
	1.1 STUDY OBJECTIVES
	1.2 MARKET DEFINITION
	1.2.1 INCLUSIONS & EXCLUSIONS
	1.3 STUDY SCOPE
	1.3.1 HEMOSTATS MARKET
	1.3.2 GEOGRAPHIC SCOPE
	1.3.3 YEARS CONSIDERED
	1.4 CURRENCY
	1.5 LIMITATIONS
	1.6 STAKEHOLDERS
	1.7 SUMMARY OF CHANGES
	2 RESEARCH METHODOLOGY (Page No. - 26)
	
	2.1 RESEARCH DATA
	2.2 RESEARCH APPROACH
	FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY
	2.2.1 SECONDARY DATA
	2.2.1.1 Key data from secondary sources
	2.2.2 PRIMARY DATA
	2.2.2.1 Primary sources
	2.2.2.2 Key data from primary sources
	2.2.2.3 Key industry insights
	2.2.2.4 Breakdown of primary interviews
	FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
	FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
	2.3 MARKET SIZE ESTIMATION
	2.3.1 BOTTOM-UP APPROACH
	2.3.1.1 Approach 1: Company revenue estimation approach
	FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
	2.3.1.2 Approach 2: Presentations of companies and primary interviews
	2.3.1.3 Growth forecast
	2.3.1.4 CAGR projections
	FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
	2.3.2 TOP-DOWN APPROACH
	FIGURE 6 HEMOSTATS INDUSTRY: TOP-DOWN APPROACH
	2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
	FIGURE 7 DATA TRIANGULATION METHODOLOGY
	2.5 MARKET SHARE ANALYSIS
	2.6 STUDY ASSUMPTIONS
	2.7 GROWTH RATE ASSUMPTIONS
	2.8 RISK ASSESSMENT
	2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET
	2.9 RECESSION IMPACT
	3 EXECUTIVE SUMMARY (Page No. - 39)
	
	FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
	FIGURE 9 HEMOSTATS INDUSTRY, BY FORMULATION, 2023 VS. 2028 (USD MILLION)
	FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
	FIGURE 11 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
	4 PREMIUM INSIGHTS (Page No. - 42)
	
	4.1 HEMOSTATS MARKET OVERVIEW
	FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
	4.2 HEMOSTATS INDUSTRY SHARE, BY TYPE, 2023 VS. 2028
	FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028
	4.3 MARKET SHARE, BY FORMULATION, 2023 VS. 2028
	FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
	4.4 MARKET SHARE, BY APPLICATION, 2023 VS. 2028
	FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
	4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
	FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD
	5 MARKET OVERVIEW (Page No. - 45)
	
	5.1 INTRODUCTION
	5.2 MARKET DYNAMICS
	FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
	5.2.1 DRIVERS
	5.2.1.1 Growing volume of surgical procedures performed
	TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021
	TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021
	5.2.1.2 Rising focus on R&D
	5.2.1.3 Rising focus on effective blood loss management in patients during surgeries
	5.2.2 RESTRAINTS
	5.2.2.1 Side effects and allergic reactions associated with hemostats
	5.2.3 OPPORTUNITIES
	5.2.3.1 Growth opportunities in emerging economies
	TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
	5.2.3.2 Growing number of hospitals
	5.2.4 CHALLENGES
	5.2.4.1 Stringent regulatory framework
	5.2.4.2 Dearth of skilled personnel for effective use of hemostats
	5.2.4.3 High cost of hemostats
	5.3 PRICING ANALYSIS
	5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
	TABLE 4 INDICATIVE PRICING FOR HEMOSTATS
	5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION
	TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS
	5.4 VALUE CHAIN ANALYSIS
	FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
	5.5 SUPPLY CHAIN ANALYSIS
	FIGURE 19 MARKET: SUPPLY CHAIN ANALYSIS
	5.6 PATENT ANALYSIS
	FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013-DECEMBER 2022)
	5.6.1 LIST OF MAJOR PATENTS
	5.7 TRADE ANALYSIS
	5.7.1 TRADE ANALYSIS FOR HEMOSTATS
	TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018-2022 (USD MILLION)
	TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018-2022 (USD MILLION)
	5.8 ECOSYSTEM ANALYSIS
	FIGURE 21 MARKET: ECOSYSTEM ANALYSIS
	5.8.1 MARKET: ROLE IN ECOSYSTEM
	5.9 PORTER’S FIVE FORCES ANALYSIS
	TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
	5.9.1 THREAT OF NEW ENTRANTS
	5.9.2 THREAT OF SUBSTITUTES
	5.9.3 BARGAINING POWER OF SUPPLIERS
	5.9.4 BARGAINING POWER OF BUYERS
	5.9.5 INTENSITY OF COMPETITIVE RIVALRY
	5.10 REGULATORY LANDSCAPE
	TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	5.10.1 NORTH AMERICA
	5.10.1.1 US
	TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
	FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
	5.10.1.2 Canada
	FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
	5.10.2 EUROPE
	FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
	5.10.3 ASIA PACIFIC
	5.10.3.1 Japan
	TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN
	5.10.3.2 China
	TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION
	5.10.3.3 India
	5.11 TECHNOLOGY ANALYSIS
	5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
	FIGURE 25 REVENUE SHIFT IN MARKET
	6 HEMOSTATS MARKET, BY TYPE (Page No. - 69)
	
	6.1 INTRODUCTION
	TABLE 16 HEMOSTATS INDUSTRY, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 17 MARKET, BY TYPE, 2022-2028 (USD MILLION)
	6.2 PRIMARY NOTES
	6.2.1 KEY PRIMARY INSIGHTS
	6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
	6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH
	TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED MARKET
	TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2022-2028 (USD MILLION)
	6.4 THROMBIN-BASED HEMOSTATS
	6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
	TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED MARKET
	TABLE 22 THROMBIN-BASED MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 23 THROMBIN-BASED MARKET, BY REGION, 2022-2028 (USD MILLION)
	6.5 COMBINATION HEMOSTATS
	6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH
	TABLE 24 MAJOR PRODUCTS IN COMBINATION MARKET
	TABLE 25 COMBINATION MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 26 COMBINATION MARKET, BY REGION, 2022-2028 (USD MILLION)
	6.6 GELATIN-BASED HEMOSTATS
	6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
	TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED MARKET
	TABLE 28 GELATIN-BASED MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 29 GELATIN-BASED MARKET, BY REGION, 2022-2028 (USD MILLION)
	6.7 COLLAGEN-BASED HEMOSTATS
	6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
	TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED MARKET
	TABLE 31 COLLAGEN-BASED MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 32 COLLAGEN-BASED MARKET, BY REGION, 2022-2028 (USD MILLION)
	6.8 OTHER HEMOSTATS
	TABLE 33 OTHER MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 34 OTHER MARKET, BY REGION, 2022-2028 (USD MILLION)
	7 HEMOSTATS MARKET, BY FORMULATION (Page No. - 81)
	
	7.1 INTRODUCTION
	TABLE 35 HEMOSTATS INDUSTRY, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 36 MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	7.2 MATRIX & GEL HEMOSTATS
	7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
	TABLE 37 MATRIX & GEL MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 38 MATRIX & GEL MARKET, BY REGION, 2022-2028 (USD MILLION)
	7.3 SHEET & PAD HEMOSTATS
	7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
	TABLE 39 SHEET & PAD MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 40 SHEET & PAD MARKET, BY REGION, 2022-2028 (USD MILLION)
	7.4 SPONGE HEMOSTATS
	7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE
	TABLE 41 SPONGE MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 42 SPONGE MARKET, BY REGION, 2022-2028 (USD MILLION)
	7.5 POWDER HEMOSTATS
	7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND
	TABLE 43 POWDER MARKET, BY REGION, 2018-2021 (USD MILLION)
	TABLE 44 POWDER MARKET, BY REGION, 2022-2028 (USD MILLION)
	8 HEMOSTATS MARKET, BY APPLICATION (Page No. - 88)
	
	8.1 INTRODUCTION
	TABLE 45 HEMOSTATS INDUSTRY, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 46 MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	8.2 PRIMARY NOTES
	8.2.1 KEY PRIMARY INSIGHTS
	8.3 ORTHOPEDIC SURGERY
	8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
	TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021
	TABLE 48 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 49 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.4 GENERAL SURGERY
	8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
	TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021
	TABLE 51 MARKET FOR GENERAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 52 MARKET FOR GENERAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.5 NEUROLOGICAL SURGERY
	8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
	TABLE 53 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 54 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.6 CARDIOVASCULAR SURGERY
	8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
	TABLE 55 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 56 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.7 RECONSTRUCTIVE SURGERY
	8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
	TABLE 57 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 58 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.8 GYNECOLOGICAL SURGERY
	8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
	TABLE 59 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 60 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
	8.9 OTHER SURGICAL APPLICATIONS
	TABLE 61 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018-2021 (USD MILLION)
	TABLE 62 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022-2028 (USD MILLION)
	9 HEMOSTATS MARKET, BY REGION (Page No. - 101)
	
	9.1 INTRODUCTION
	TABLE 63 HEMOSTATS INDUSTRY, BY REGION, 2018-2021 (USD MILLION)
	TABLE 64 MARKET, BY REGION, 2022-2028 (USD MILLION)
	9.2 NORTH AMERICA
	FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
	TABLE 65 NORTH AMERICA: MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
	TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
	TABLE 67 NORTH AMERICA: MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 68 NORTH AMERICA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	TABLE 69 NORTH AMERICA: MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 70 NORTH AMERICA: MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	TABLE 71 NORTH AMERICA: MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 72 NORTH AMERICA: MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	9.2.1 NORTH AMERICA: RECESSION IMPACT
	9.2.2 US
	9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats
	TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.2.3 CANADA
	9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats
	TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021
	TABLE 76 CANADA: KEY MACROINDICATORS
	TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3 EUROPE
	TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
	TABLE 80 EUROPE: MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
	TABLE 81 EUROPE: MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 82 EUROPE: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	TABLE 83 EUROPE: MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 84 EUROPE: MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	TABLE 85 EUROPE: MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 86 EUROPE: MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	9.3.1 EUROPE: RECESSION IMPACT
	9.3.2 GERMANY
	9.3.2.1 High healthcare expenditure in Germany to favor market growth
	TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021
	TABLE 88 GERMANY: KEY MACROINDICATORS
	TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.3 UK
	9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth
	TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021
	TABLE 92 UK: KEY MACROINDICATORS
	TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.4 FRANCE
	9.3.4.1 Presence of well-established healthcare system to propel market growth
	TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021
	TABLE 96 FRANCE: KEY MACROINDICATORS
	TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.5 ITALY
	9.3.5.1 Increasing volume of surgeries to drive demand for hemostats
	TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021
	TABLE 100 ITALY: KEY MACROINDICATORS
	TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 102 ITALY: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.6 SPAIN
	9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth
	TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021
	TABLE 104 SPAIN: KEY MACROINDICATORS
	TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 106 SPAIN: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.7 RUSSIA
	9.3.7.1 Long-term healthcare investment initiatives by government to support market growth
	TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 108 RUSSIA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.8 SWITZERLAND
	9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures
	TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021
	TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 111 SWITZERLAND: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.9 BELGIUM
	9.3.9.1 Increasing demand for value-based healthcare services to drive market growth
	TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021
	TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.3.10 REST OF EUROPE
	TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
	TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4 ASIA PACIFIC
	FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT
	TABLE 118 ASIA PACIFIC: MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
	TABLE 119 ASIA PACIFIC: MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
	TABLE 120 ASIA PACIFIC: MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 121 ASIA PACIFIC: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	TABLE 122 ASIA PACIFIC: MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 123 ASIA PACIFIC: MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	TABLE 124 ASIA PACIFIC: MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 125 ASIA PACIFIC: MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	9.4.1 ASIA PACIFIC: RECESSION IMPACT
	9.4.2 CHINA
	9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth
	TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.3 JAPAN
	9.4.3.1 Strong healthcare system and rising geriatric population to support market growth
	TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.4 INDIA
	9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth
	TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.5 AUSTRALIA
	9.4.5.1 Rising prevalence of chronic diseases to drive market growth
	TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 133 AUSTRALIA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.6 SOUTH KOREA
	9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats
	TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021
	TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 136 SOUTH KOREA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.7 SINGAPORE
	9.4.7.1 Government initiatives to promote healthcare services to support market growth
	TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 138 SINGAPORE: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.8 NEW ZEALAND
	9.4.8.1 Increasing number of hip fractures to propel market growth
	TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 140 NEW ZEALAND: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.9 INDONESIA
	9.4.9.1 Lucrative growth opportunities for players to boost market
	TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 142 INDONESIA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.10 MALAYSIA
	9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth
	TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 144 MALAYSIA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.4.11 REST OF ASIA PACIFIC
	TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.5 LATIN AMERICA
	TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
	TABLE 148 LATIN AMERICA: MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
	TABLE 149 LATIN AMERICA: MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 150 LATIN AMERICA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	TABLE 151 LATIN AMERICA: MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 152 LATIN AMERICA: MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	TABLE 153 LATIN AMERICA: MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 154 LATIN AMERICA: MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	9.5.1 LATIN AMERICA: RECESSION IMPACT
	9.5.2 BRAZIL
	9.5.2.1 Brazil to dominate Latin American market for hemostats
	TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.5.3 MEXICO
	9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico
	TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.5.4 REST OF LATIN AMERICA
	TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
	9.6 MIDDLE EAST & AFRICA
	9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
	TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
	TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2022-2028 (USD MILLION)
	TABLE 163 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
	TABLE 164 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
	TABLE 165 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
	TABLE 166 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
	9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
	10 COMPETITIVE LANDSCAPE (Page No. - 161)
	
	10.1 OVERVIEW
	10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
	10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
	TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES
	10.3 REVENUE ANALYSIS
	FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2018-2022)
	10.4 MARKET SHARE ANALYSIS
	FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2022)
	TABLE 168 HEMOSTATS INDUSTRY: DEGREE OF COMPETITION
	10.5 COMPANY EVALUATION MATRIX
	10.5.1 LIST OF EVALUATED VENDORS
	10.5.2 STARS
	10.5.3 EMERGING LEADERS
	10.5.4 PERVASIVE PLAYERS
	10.5.5 PARTICIPANTS
	FIGURE 30 HEMOSTATS INDUSTRY: COMPANY EVALUATION MATRIX (2022)
	10.5.6 COMPANY FOOTPRINT
	10.5.6.1 Product & regional footprint analysis
	FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY
	TABLE 169 HEMOSTATS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS
	TABLE 170 COMPANY FOOTPRINT, BY TYPE
	TABLE 171 COMPANY FOOTPRINT, BY REGION
	10.6 START-UP/SME EVALUATION MATRIX
	10.6.1 PROGRESSIVE COMPANIES
	10.6.2 RESPONSIVE COMPANIES
	10.6.3 DYNAMIC COMPANIES
	10.6.4 STARTING BLOCKS
	FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)
	10.7 COMPETITIVE SCENARIO
	10.7.1 PRODUCT LAUNCHES & APPROVALS
	TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018-OCTOBER 2023)
	10.7.2 DEALS
	TABLE 173 KEY DEALS (JANUARY 2018-OCTOBER 2023)
	10.7.3 OTHER KEY DEVELOPMENTS
	TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018-OCTOBER 2023)
	11 COMPANY PROFILES (Page No. - 174)
	
	(Business overview, Products offered, Recent developments & MnM View)*
	11.1 KEY PLAYERS
	11.1.1 JOHNSON & JOHNSON
	TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW
	FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
	11.1.2 BAXTER INTERNATIONAL
	TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW
	FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)
	11.1.3 PFIZER INC.
	TABLE 177 PFIZER INC.: BUSINESS OVERVIEW
	FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022)
	11.1.4 B. BRAUN SE
	TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW
	FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022)
	11.1.5 BECTON, DICKINSON AND COMPANY
	TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
	FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
	11.1.6 TELEFLEX INCORPORATED
	TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW
	FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)
	11.1.7 MEDTRONIC PLC
	TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW
	FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
	11.1.8 HEMOSTASIS, LLC
	TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW
	11.1.9 STRYKER CORPORATION
	TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW
	FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022)
	11.1.10 INTEGRA LIFESCIENCES
	TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
	FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)
	11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC
	TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW
	FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)
	11.1.12 SAMYANG HOLDINGS CORPORATION
	TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW
	FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)
	*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
	11.2 OTHER PLAYERS
	11.2.1 MARINE POLYMER TECHNOLOGIES, INC.
	11.2.2 GELITA MEDICAL GMBH
	11.2.3 DILON TECHNOLOGIES, INC.
	11.2.4 BETATECH MEDICAL
	11.2.5 MERIL LIFE SCIENCES PVT. LTD.
	11.2.6 BIOCER ENTWICKLUNGS-GMBH
	11.2.7 UNILENE
	11.2.8 KATSAN MEDICAL DEVICES
	11.2.9 TRICOL BIOMEDICAL
	11.2.10 3-D MATRIX MEDICAL TECHNOLOGY
	11.2.11 HEMOSTAT MEDICAL GMBH
	11.2.12 MEDTRADE PRODUCTS LIMITED
	11.2.13 ALTAYLAR MEDICAL
	12 APPENDIX (Page No. - 215)
	
	12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
	12.2 CUSTOMIZATION OPTIONS
	12.3 RELATED REPORTS
	12.4 AUTHOR DETAILS